A Study of Bispecific Antibody QLS31901 in Patients With Advanced or Metastatic Malignancies
Status:
Recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
This is a Phase 1, open label, non-randomised, dose-escalation single agent study with
expansion cohorts for dose confirmation/safety and preliminary efficacy of QLS31901 in
advanced or metastatic malignancies